

Contains Exact Match Begins With
 Name Code Property Relationship
Source:

NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)

[Home](#) | [NCIt Hierarchy](#) | [Sources](#) | [Help](#) | [Visited Concepts](#)

AE37 Peptide/GM-CSF Vaccine (CUI CL376182)

[Suggest changes to this concept](#)
[Add to Cart](#)
[Terms & Properties](#) | [Synonym Details](#) | [Relationships](#) | [By Source](#) | [View All](#)

Terms & Properties

Concept Unique Identifier (CUI): CL376182

NCI Thesaurus Code: C91719 ([see NCI Thesaurus info](#))

Semantic Type: Pharmacologic Substance

Semantic Type: Immunologic Factor

NCIt Definition: A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The li-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.

PDQ Definition: A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The li-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. Check for [active clinical trials](#) using this agent. ([NCI Thesaurus](#))

Synonyms & Abbreviations: ([see Synonym Details](#))

AE37 Peptide/GM-CSF Vaccine

External Source Codes:

NCI Thesaurus Code	C91719 (see NCI Thesaurus info)
PDQ Closed Trial Search ID	564693
PDQ Open Trial Search ID	564693 (check for NCI PDQ open clinical trial info)

Other Properties:

Name	Value	Source
Contributing_Source	CTRP	NCI
DATE_FIRST_PUBLISHED	2007-08-27	PDQ
DATE_LAST_MODIFIED	2010-12-16	PDQ
NCI_THESAURUS_CODE	C91719	PDQ
ORIG_STY	Drug/agent	PDQ

Additional Concept Data: (none)

URL to Bookmark: [https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=CL376182](https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI%20Metathesaurus&code=CL376182)